Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18882492 | 0.97 | TRPV1 (0.49) | TRPV1MEN1MAPTKMT2ANPSR1 | |
| SCHEMBL18645309 | 0.83 | ITGB3 (0.41) | TRPV1MMP1MMP3MMP9ALDH1A1 | |
| SCHEMBL18882491 | 0.82 | ITGB3 (0.42) | TRPV1 | |
| SCHEMBL18645310 | 0.81 | FOLH1 (0.43) | MEN1MAPTKMT2ANPSR1FOLH1 | |
| SCHEMBL13492840 | 0.79 | MMP1 (0.48) | MEN1MAPTKMT2ANPSR1CTSK | |
| SCHEMBL30887591 | 0.75 | ACE (0.60) | MEN1MAPTKMT2AMMP1MMP3 | |
| SCHEMBL30291800 | 0.75 | ACE (0.60) | MEN1MAPTKMT2AMMP1MMP3 | |
| SCHEMBL11977591 | 0.75 | FOLH1 (0.61) | MEN1MAPTKMT2ANPSR1FOLH1 | |
| SCHEMBL27706581 | 0.74 | CASP1 (0.50) | MAPTCTSKMMP1MMP3MMP9 | |
| SCHEMBL2063189 | 0.74 | CASP1 (0.50) | MAPTCTSKMMP1MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200330625-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | On Target Laboratories, Inc. | 2020-10-22 | — | — | US | disclosed |
| US-20170145035-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | On Target Laboratories, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-20170145035-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | On Target Laboratories, Inc. | 2017-05-25 | — | — | US | disclosed |
| WO-2017044443-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | On Target Laboratories, LLC (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044445-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | On Target Laboratories, LLC (US) | 2017-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145035-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | ERAL1, TK2, PYCR1 | TRPV1 811/4885MEN1 2663/4885MAPT 2188/4885 |
| US-20200330625-A1 | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | ERAL1, TK2, PYCR1 | TRPV1 811/4885MEN1 2663/4885MAPT 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.